MARKED-UP COPY

when R^1 represents a hydrogen atom and R^2 represents a group represented by the above general formula (F), then it is not possible that R^{19} represents a hydrogen atom and R^{20} represents a tert-butoxycarbonyl group.

2. The 2, 3-dihydro-6-nitroimidazo[2,1-b] oxazole compound represented by the following general formula (1'), as claimed in claim 1:

or a pharmaceutically acceptable salt thereof



(1')

wherein R^1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0 to 6, and R^2 represents a group represented by general formula (A'), (B'), (C'), (D'), (E'), (F') or (G') indicated below, and further, R^1 and $-(CH_2)_nR^2$ may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms,so as to form a spiro ring represented by general formula (H') indicated below:

a group represented by the following general formula (A'):

$-OR^3$ (A')

piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
(S)-2-methyl-6-nitro-2-[4-(4-trifluoromethylphenyl)-piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
(R)-2-methyl-6-nitro-2-[4-(4-trifluoromethylphenyl)-piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
2-methyl-6-nitro-2-[4-(5-trifluoromethoxylbenzofuran-2-ylmethyleneamino)piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
(S)-2-methyl-6-nitro-2-[4-(5-trifluoromethoxyl-benzofuran-2-ylmethyleneamino)piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
(R)-2-methyl-6-nitro-2-[4-(5-trifluoromethoxyl-benzofuran-2-ylmethyleneamino)piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
2-methyl-6-nitro-2-[4-(5-trifluoromethylbenzofuran-2-ylmethyleneamino)piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
(S)-2-methyl-6-nitro-2-[4-(5-trifluoromethylbenzofuran-2-ylmethyleneamino)piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
(R)-2-methyl-6-nitro-2-[4-(5-trifluoromethylbenzofuran-2-ylmethyleneamino)piperazin-1-ylmethyl]-2,3-dihydroimidazo[2,1-b]oxazole,
2-methyl-6-nitro-2-{4-[4-(4-chlorophenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole,
(S)-2-methyl-6-nitro-2-{4-[4-(4-chlorophenoxy)-piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole,

1375 1375
~~1775~~

(R)-2-methyl--6-nitro-2-{4-[4-(4-chlorophenoxy)- piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo [2.1-b] oxazole,
2-methyl-6-nitro-2-{4-[4-(4-trifluoromethylphenoxy)-piperidin-1-yl] phenoxymethyl}-2, 3-dihydroimidazo [2, 1-b] oxazole
(S)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethyl-phenoxy) piperidin-1-yl] phenoxymethyl}-2, 3-dihydroimidazo [2, 1-b] oxazole
(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethyl-phenoxy) piperidin-1-yl] phenoxymethyl}-2, 3-dihydroimidazo [2,1-b] oxazole,
2-methyl-6-nitro-2-{4-[1-(4-chlorobenzyl) piperidin-4-yl] phenoxymethyl} 2, 3-dihydroimidazo [2,1-b] oxazole, (S) -2-methyl-6-nitro-2-{4-[1-(4-chlorobenzyl) piperidin -4-yl] phenoxymethyl} -2, 3-dihydroimidazo [2, 1-b] oxazole,
or
(R) -2-methyl-6-nitro-2-{4-[1-chorobenzyl) piperidin-4-yl] phenoxymethyl} -2, 3-dihydroimidazo [2,1-b] oxazole ~~and~~ pharmaceutically acceptable salts ~~thereof.~~

for each of above listed compounds

or a

5. (R) -2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxy-phenoxy) piperidin-1yl] phenoxymethyl} -2,3-dihydroimidazo [2,1-b] oxazole ~~and~~ a pharmaceutically acceptable salt

or

thereof

6. A pharmaceutical composition which is an antitubercular agent comprising, as an active ingredient 1 to 70% by weight of the 2, 3-dihydro-6-nitroimidazo [2, 1-b] oxazole compound as claimed in claim 1.

or a pharmaceuticall acceptable salt thereof

7. The pharmaceutical composition which is an antitubercular agent comprising, as an active ingredient, 1 to 70% by weight of at least one compound selected from the 2, 3-dihydro-6-nitroimidazo [2, 1-b] oxazole compounds as claimed in claim 4.

or a pharmaceutically accepatable salt thereof

8. The pharmaceutical composition which is an antitubercular agent comprising, as an active ingredient, 1 to 70% by weight of the 2, 3,-dihydro-6-nitroimidazo [2, 1-b] oxazole compound as claimed in claim 5.

or a pharmaceutically accepatable salt thereof

9. A method for producing a compound represented by the following general formula (1a):



(1a)

wherein R^1, R^2 and n are defined as the same as in claim 1, said production method comprising: the reaction of a 4-nitroimidazole compound represented by the following general formula (2):



(2)

wherein X_1 represents a halogen atom or nitro group, with an epoxy compound represented by the following general formula (3a):



(3a)

wherein R^1, R^2 and n are defined as the same as in claim 1, so as to obtain a compound represented by the following general formula (4a):



wherein R^1, R^2 and n are defined as the same as in claim 1, and X_1 represents a halogen atom or nitro group; and the following ring closure of the obtained compound represented by the above general formula (4a).

10. The method for producing a compound represented by the following general formula (1b):



(1b)

wherein R^1 is as defined in claim 1, and R^{2a} represents a group represented by the general formula (A), (B), (E) or (F) as claimed in claim 1,
said production method comprising: the reaction of a compound represented by the following general formula (3b):



(3b)

wherein R^1 is as defined in claim 1, and X_1 represents a halogen atom or nitro group, with a compound (5) represented by the following general formula $R^{2a}H$(5) or a salt thereof,

wherein R^{2a} represents the group represented by the general formula (A), (B), (E) or (F) according to claim 1, so as to obtain a compound represented by the following general formula (4b):



(4b)

wherein R^1 is as defined in claim 1, R^{2a} represents the group represented by the general formula (A), (B), (E) or (F) according to claim 1, and X_1 represents a halogen atom or nitro group; and

the following ring closure of the obtained compound represented by the above general formula (4b).

11. The method for producing a compound represented by the following general formula (1c):



(1c)

wherein R^{41} is as defined in claim 1,

said production method comprising: the reaction of a compound represented by the following general formula (2):



(2)

wherein X_1 represents a halogen atom or nitro group, with a compound represented by the following general formula (3c):



(3c)

wherein R^{41} is as defined in claim 1,
so as to obtain a compound represented by the following general formula (4c):



(4c)

wherein R^{41} is as defined in claim 1, and X_1 represents a halogen atom or nitro group; and
the following ring closure of the obtained compound represented by the above general formula (4c).

Dated this 8th day of April 2005

OF L. S. DAVAR & CO.
APPLICANTS' AGENT